https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Risk of secondary progressive multiple sclerosis: a longitudinal study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38068 p <0.001), longer disease duration (HR=1.01, p=0.038), a higher Expanded Disability Status Scale score (HR=1.30, p<0.001), more rapid disability trajectory (HR=2.82, p<0.001) and greater number of relapses in the previous year (HR=1.07, p=0.010) were independently associated with an increased risk of secondary progressive multiple sclerosis. Improving disability (HR=0.62, p=0.039) and disease-modifying therapy exposure (HR=0.71, p=0.007) were associated with a lower risk. Recent cerebral magnetic resonance imaging activity, evidence of spinal cord lesions and oligoclonal bands in the cerebrospinal fluid were not associated with the risk of conversion. Conclusion:Risk of secondary progressive multiple sclerosis increases with age, duration of illness and worsening disability and decreases with improving disability. Therapy may delay the onset of secondary progression.]]> Wed 24 May 2023 12:22:34 AEST ]]> The effectiveness of natalizumab vs fingolimod - A comparison of international registry studies https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38113 Wed 04 Aug 2021 11:40:28 AEST ]]> Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53990 Thu 25 Jan 2024 13:04:15 AEDT ]]> Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52624 Thu 19 Oct 2023 14:15:33 AEDT ]]> Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52249 Thu 05 Oct 2023 14:07:20 AEDT ]]> Confirmed disability progression as a marker of permanent disability in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52212 88% likely to be sustained (events with score ˃1.5). Conclusions: Clinicodemographic characteristics of 6-month confirmed disability progression events identify those at high risk of sustained long-term disability. This knowledge will allow future trials to better assess the effect of therapy on long-term disability accrual.]]> Thu 05 Oct 2023 10:22:58 AEDT ]]> Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48108 Mon 27 Feb 2023 15:18:00 AEDT ]]> Predictors of treatment switching in the Big Multiple Sclerosis Data Network https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54767 Mon 11 Mar 2024 15:00:30 AEDT ]]> Disability accrual in primary and secondary progressive multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51685 Fri 15 Sep 2023 09:36:29 AEST ]]> Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51340 Fri 01 Sep 2023 13:35:50 AEST ]]>